ReviewAvicenna journal of medicine2025
Efficacy and Safety of Biological Agents in Giant Cell Arteritis: An Updated Meta-Analysis.
Review in Avicenna journal of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Giant cell arteritis (GCA), impacting individuals over 50, causes vision loss, headaches, and jaw pain due to inflammation from proinflammatory cytokines and growth factors. Standard treatment involves glucocorticoids, with tocilizumab and tumor necrosis factor (TNF) inhibitors currently being studied. Method: This meta-analysis, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses and Meta-analysis of Observational Studies in Epidemiology guidelines, included adult GCA patients treated with biological agents. The search covered PubMed, Medline, Embase, and Scopus until October 2023, excluding nonhuman, pediatric, non-English, and nonrandomized studies. Data were analyzed using Review Manager 5.4, with random effects models calculating odds ratios (ORs) and 95% confidence intervals (CIs). Result: A meta-analysis of 11 studies ( Conclusion: Tocilizumab effectively induces remission in GCA patients, while abatacept and TNF inhibitors offer minimal benefits with increased infection risks, according to this meta-analysis. Treatment decisions should consider these factors, and larger studies are necessary to evaluate the safety and efficacy of biological agents in managing GCA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.